文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

血浆宏基因组测序检测与定量ICU疑似脓毒症患者细菌DNA的初步研究

Plasma metagenomic sequencing to detect and quantify bacterial DNA in ICU patients suspected of sepsis: A proof-of-principle study.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论外科创伤ICU疑似脓毒症患者活动性感染时血浆总细菌DNA分数升高,富集后病原特异性DNA可检测,系列变化或反映治疗反应。

该初步研究纳入外科创伤ICU疑似脓毒症患者30例,采集基线、第7天和第14天血浆样本共72份,行血浆DNA宏基因组测序及计算分类,检测并定量总细菌DNA分数和病原特异性细菌DNA分数;采用基于短片段长度选择的富集方法提高灵敏度。感染时样本总细菌DNA分数中位数较无感染样本高1.6倍(0.011% vs 0.0068%,p<0.001);17例入组时有活动性感染且有随访样本的患者基线总细菌DNA分数高于下一份样本(p<0.001);富集后配对样本细菌DNA分数平均增加16.9倍;17份鉴定出细菌病原体的样本中13份(76.5%)检出病原特异性DNA。

要点

  • 外科创伤ICU疑似脓毒症患者中,感染时血浆总细菌DNA分数中位数为0.011%,无感染时为0.0068%,前者高1.6倍(p<0.001)。
  • 17例入组时有活动性感染且至少有一份随访样本的患者,基线总细菌DNA分数高于下一份样本(p<0.001),提示系列变化可能反映治疗反应。
  • 采用基于短片段长度选择的富集方法后,配对样本细菌DNA分数平均增加16.9倍。
  • 17份采集时已鉴定出细菌病原体的样本中,13份(76.5%)检出病原特异性DNA。
  • 该研究为初步研究,证据等级为流行病学/预后Level V,尚不能作为床旁决策阈值。

适用人群与场景

  • 外科创伤ICU中疑似脓毒症的患者,共30例,采集基线(脓毒症诊断检查时)、第7天和第14天血浆样本。

诊断标准与关键阈值

  • 原文未提及脓毒症的诊断标准或评分界值。
  • 原文未提及细菌DNA分数的启动或停止阈值。

处置流程与药物剂量

  • 原文未提及基于细菌DNA检测结果的处置流程或药物剂量。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为初步研究(proof-of-principle),纳入30例外科创伤ICU疑似脓毒症患者,分析72份血浆样本。
  • 17例入组时有活动性感染且至少有一份随访样本的患者,基线总细菌DNA分数高于下一份样本(p<0.001)。
  • 富集后配对样本细菌DNA分数平均增加16.9倍。
  • 17份采集时已鉴定出细菌病原体的样本中,13份(76.5%)检出病原特异性DNA。

证据类型、等级与局限

  • 证据类型为初步研究(proof-of-principle),证据等级为流行病学/预后Level V。
  • 局限:样本量小(30例患者,72份样本),单中心外科创伤ICU,未提及盲法或对照,需前瞻性验证。

对床旁实践的改变

  • 该初步研究提示血浆细菌DNA定量及富集后病原特异性DNA检测或可用于ICU疑似脓毒症患者的病原检测和系列监测,但证据等级为Level V,尚不能改变现有床旁诊疗决策。
  • 原文未提及适用与不适用人群的明确界限,临床使用需谨慎。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Timely recognition of sepsis and identification of pathogens can improve outcomes in critical care patients but microbial cultures have low accuracy and long turnaround times. In this proof-of-principle study, we describe metagenomic sequencing and analysis of nonhuman DNA in plasma. We hypothesized that quantitative analysis of bacterial DNA (bDNA) levels in plasma can enable detection and monitoring of pathogens.

METHODS: We enrolled 30 patients suspected of sepsis in the surgical trauma intensive care unit and collected plasma samples at the time of diagnostic workup for sepsis (baseline), and 7 days and 14 days later. We performed metagenomic sequencing of plasma DNA and used computational classification of sequencing reads to detect and quantify total and pathogen-specific bDNA fraction. To improve assay sensitivity, we developed an enrichment method for bDNA based on size selection for shorter fragment lengths. Differences in bDNA fractions between samples were evaluated using t test and linear mixed-effects model, following log transformation.

RESULTS: We analyzed 72 plasma samples from 30 patients. Twenty-seven samples (37.5%) were collected at the time of infection. Median total bDNA fraction was 1.6 times higher in these samples compared with samples with no infection (0.011% and 0.0068%, respectively, p < 0.001). In 17 patients who had active infection at enrollment and at least one follow-up sample collected, total bDNA fractions were higher at baseline compared with the next sample (p < 0.001). Following enrichment, bDNA fractions increased in paired samples by a mean of 16.9-fold. Of 17 samples collected at the time when bacterial pathogens were identified, we detected pathogen-specific DNA in 13 plasma samples (76.5%).

CONCLUSION: Bacterial DNA levels in plasma are elevated in critically ill patients with active infection. Pathogen-specific DNA is detectable in plasma, particularly after enrichment using selection for shorter fragments. Serial changes in bDNA levels may be informative of treatment response.

LEVEL OF EVIDENCE: Epidemiologic/Prognostic, Level V.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Kisat MT, Odenheimer-Bergman A, Markus H, et al. Plasma metagenomic sequencing to detect and quantify bacterial DNA in ICU patients suspected of sepsis: A proof-of-principle study. J Trauma Acute Care Surg. 2021. PMID: 34510074. doi:10.1097/TA.0000000000003396

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。